Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026

FG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results
/in Clinical Trial, Metastatic, Phase 2/by MaxMacrophage-Drug Conjugates: A New Frontier in Cancer Treatment
/in Delivery, Preclinical Research/by MaxAndrogen Receptor Inhibition Enhances Immune Response in Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxThe Phase 1 ACCEL Trial: Actinium-225-PSMA-62
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 3 Trial of TLX591 Kicks Off in Miami
/in Clinical Trial, Metastatic, Phase 3/by MaxCancer Vaccine? Yes, Universal Please…
/in Immunotherapy, Preclinical Research/by MaxGoogle’s AI Co-Scientist: A Leap Forward in Biomedical Research
/in Artificial Intelligence/by MaxOncoACP3: A Potential Game-Changer in Prostate Cancer Theranostics —Why?
/in Clinical Trial, Metastatic, Phase 1/by Max